Outcomes and prognostic impact of trisomy 8 in acute myeloid leukemia patients treated with intensive chemotherapy

Cytogenetic aberrations remain a cornerstone of AML classification, prognostication, and treatment allocation [ 1 , 2 ]. Trisomy 8 (+8) is a common numerical cytogenetic aberration found in approximately 10–15% of AML cases, either as the sole cytogenetic abnormality, in combination with other recurrent aberrations, or as part of a complex karyotype [ 2 , 3 ]. Currently, +8 without favorable or adverse defining abnormalities is categorized as intermediate-risk according to European LeukemiaNet 2022 risk classification (ELN2022) [ 1 ], despite conflicting results regarding the prognostic impact [ 4 , 5 , 6 , 7 , 8 ].